| Unique ID issued by UMIN | UMIN000018333 |
|---|---|
| Receipt number | R000021217 |
| Scientific Title | Post marketing surveillance of Edirol |
| Date of disclosure of the study information | 2015/08/01 |
| Last modified on | 2016/05/20 14:13:05 |
Post marketing surveillance of Edirol
Post marketing surveillance of Edirol
Post marketing surveillance of Edirol
Post marketing surveillance of Edirol
| Japan |
Osteoporosis
| Medicine in general | Orthopedics |
Others
NO
-Adverse drug reaction under conditions of actual drug use
- Factors potentially affecting safety or efficacy
- Safety and efficacy in male patients
- Hypercalcemia
Safety,Efficacy
Adverse reaction incidence
Observational
| Not applicable |
| Not applicable |
Male and Female
Patients who have no previous treatment with Edirol for osteoporosis
No criteria
3000
| 1st name | |
| Middle name | |
| Last name | Joji Mochizuki |
Chugai Pharmaceutical Co.Ltd
Pharmacovigilance Dept
1-1 Nihonbashi-muromachi 2-chome,Chuo-ku Tokyo,Japan
03-3273-0905
mochizukijuj@chugai-pharm.co.jp
| 1st name | |
| Middle name | |
| Last name | Makoto Nomura |
Chugai Pharmaceutical Co.Ltd
Pharmacovigilance Dept
1-1 Nihonbashi-muromachi 2-chome,Chuo-ku Tokyo,Japan
03-3273-0905
nomuramkt@chugai-pharm.co.jp
Chugai Pharmaceutical Co.Ltd
Chugai Pharmaceutical Co.Ltd
Profit organization
NO
| 2015 | Year | 08 | Month | 01 | Day |
Unpublished
Completed
| 2011 | Year | 05 | Month | 23 | Day |
| 2011 | Year | 07 | Month | 01 | Day |
Adverse events
Bone massdensity, bone metabolism marker
and fracture
| 2015 | Year | 07 | Month | 16 | Day |
| 2016 | Year | 05 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021217